InsidersTradesSigma
Simcere Pharmaceutical Group Ltd. Stock: price and insider trades · Hong Kong · HKEX
Track the Simcere Pharmaceutical Group Ltd. share price and the full management transaction log of the company, a listed equity based in Hong Kong. Shares trade on HK HK, under the oversight of HKEX. Operating in the Health Care sector, Simcere Pharmaceutical Group Ltd. has logged 10 insider filings. Market capitalisation: €31.4bn. The latest transaction was disclosed on 9 July 2026 (Sale). Among the most active insiders: REN Jinsheng. The full history is free.
10
Insider Decl.
0
Thresholds
·
4 ops.
Buy Volume
·
5 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Simcere Pharmaceutical Group Ltd. Strong Buy (bullish), based on 5 analysts. Average price target: HK$17.81.
19Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 5,261 of 26,212 companies
66.8
score / 100
Value50
Quality83
FCF yld3.7%
Earn yld4.3%
EV/EBITDA16.3x
ROE16%
Gross mgn82%
Net mgn17%
Debt/EBITDA0.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 9 July 2026
Declarations10 total
100,000 sharesShareXHKGHKEX:DA20260709E00489
100,000 sharesShareXHKGHKEX:DA20260617E00028
Ideal exit: 12 Mar 2027 (T+270)
100,000 sharesShareXHKGHKEX:DA20260615E00354
Ideal exit: 7 Mar 2027 (T+270)
283,334 sharesShareXHKGHKEX:DA20260427E00010
3,000,000 sharesShareXHKGHKEX:DA20260427E00009
44,952,853 sharesShareXHKGHKEX:DA20260413E00571
10 of 10 declarations
About Simcere Pharmaceutical Group Ltd.
Simcere Pharmaceutical Group Ltd. is a company focused on the research, development, and commercialization of innovative pharmaceuticals in China. It primarily concentrates on treatments for oncology and autoimmune diseases.